ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center

ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心

• 批准号: 9894764
• 负责人: DAVID P. CARBONE
• 金额: $ 75.08万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-14 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9894764
• 关键词: American College of Radiology Imaging Network; Area; Award; BRAF gene; Biological Markers; Center for Translational Science Activities; Chest; Clinical; Clinical Data; Clinical Sciences; Clinical Trials; Clinical Trials Network; Collaborations; Combined Modality Therapy; Detection; Development; Disease; EGFR inhibition; Early Diagnosis; Eastern Cooperative Oncology Group; Enrollment; Epidermal Growth Factor Receptor; Excision; Funding; Genomics; Goals; Grant; Immunologic Markers; Immunotherapy; Institution; Leadership; Lung; Lung Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of thorax; Molecular; Molecular Abnormality; Molecular Analysis; Mutation; National Clinical Trials Network; Non-Small-Cell Lung Carcinoma; Operative Surgical Procedures; Patient-Focused Outcomes; Patients; Pilot Projects; Plasma; Plasma Cells; Play; Precision Medicine Initiative; Precision therapeutics; Prevention; Process; Proteomics; ROS1 gene; Recurrence; Research; Research Personnel; Residual Neoplasm; Resistance; Risk; Risk stratification; Role; STK11 gene; Science; Specimen; Technology; Testing; Time; Translational Research; Work; biomarker development; biomarker discovery; biomarker evaluation; biomarker-driven; cell free DNA; checkpoint inhibition; chemotherapy; clinical care; cohort; companion diagnostics; driver mutation; drug development; epigenetic marker; epigenomics; improved; improved outcome; inhibitor/antagonist; innovation; lung cancer screening; lung small cell carcinoma; next generation; novel; novel marker; novel strategies; personalized medicine; phase 3 study; programmed cell death ligand 1; programs; prospective; targeted agent; targeted treatment; tumor

PROJECT SUMMARY/ABSTRACT The ECOG-ACRIN Thoracic Integrated Translational Research Center (EA-ITSC) comprises a team of accomplished researchers with a proven track record of collaborative work to improve outcomes for patients with lung cancer. The EA-ITSC, funded in 2014 by the NCI (U10) at the same time as the formation of the National Clinical Trials Network (NCTN), has played a major role in developing novel approaches for risk stratification, molecular testing, and treatment of lung cancer. This group has also been responsible for guiding the development of biomarker-driven clinical trials initiated by the ECOG-ACRIN Thoracic Malignancies Committee. Our highly collaborative team approach includes sharing specimens across institutions, conducting pilot projects that are of direct relevance to NCTN trials and guiding the translational research components of all newly developed ECOG-ACRIN thoracic malignancies trials. Our overarching goal is to develop novel biomarkers to enhance the efficacy of immunotherapy, overcome resistance to targeted agents and to identify combination treatment approaches to enhance the efficacy of existing therapies in lung cancer within the context of the NCTN. With this application, we propose to continue our research work with direct relevance to the NCTN, with the following specific aims: 1) To develop genomic, epigenomic, and proteomics approaches to enhance biomarker discovery efforts in ongoing and planned ECOG-ACRIN studies; 2) To conduct pilot studies on existing ECOG- ACRIN and institutional lung cancer tumor specimens that will lead to prospective NCTN clinical trials; and 3) To guide the development of translational research components of ECOG-ACRIN Thoracic trials and promote collaborations with lung cancer SPORE and P01 institutions. The EA-ITSC will have a robust pilot projects program from years 2-6 of this award that will invite participation from all the NCTN network groups, institutions with lung cancer SPORE and P01 awards, to bring the best science to NCTN clinical trials.

项目总结/文摘